Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

December 11, 2018

Primary Completion Date

August 14, 2019

Study Completion Date

September 14, 2019

Conditions
Cold Hypersensitivity
Interventions
DRUG

Ucha-Shinki-Hwan

"Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g"

DRUG

Placebo

placebo granule

Trial Locations (1)

02447

Kyung Hee University medical center at Gangdong, Seoul

All Listed Sponsors
collaborator

Kyunghee University Medical Center

OTHER

collaborator

Kyung Hee University Hospital at Gangdong

OTHER

collaborator

Semyung University Affiliated Oriental Medical Hospital

OTHER

collaborator

Sangji University Oriental Medical Hospital

UNKNOWN

lead

Gachon University Gil Oriental Medical Hospital

OTHER

NCT03790033 - Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial | Biotech Hunter | Biotech Hunter